Blog
RSS FeedPosted by Michael Wonder on 18 Jul 2019
Two cancer immunotherapy makers face different situations in reimbursement talks
18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence. ...
Posted by Michael Wonder on 03 Jul 2019
Eli Lilly Korea gains further reimbursement for psoriasis treatment Taltz
1 July 2019 - The Korean branch of Eli Lilly said that it had gained additional reimbursement for its psoriasis ...
Posted by Michael Wonder on 22 Jun 2019
Delayed patient access to innovative medical technologies in South Korea: a lead-time analysis of reimbursement coverage determinations
20 June 2019 - Timely access to innovative medical technologies driven by accelerated patient access pathways can substantially improve the health ...
Posted by Michael Wonder on 13 Jun 2019
Role of health technology assessment in drug policies: Korea
13 June 2019 - South Korea is the first Asian country to mandate the submission of pharmacoeconomic data for reimbursement decision ...
Posted by Michael Wonder on 13 Jun 2019
Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific Region: the case of Australia, China, India, Malaysia, New Zealand, and South Korea
13 June 2019 - Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of ...
Posted by Michael Wonder on 13 Jun 2019
Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug
12 June 2019 - Korean patients with severe atopic dermatitis gathered in front of the National Assembly on Tuesday to ...
Posted by Michael Wonder on 30 May 2019
HIV prevention pill to get insurance benefit in Korea
30 May 2019 - The local medical community is likely to use a drug to prevent HIV infection in earnest. ...
Posted by Michael Wonder on 21 May 2019
Roche’s breast cancer drug gains more insurance benefits
21 May 2019 - The Ministry of Health and Welfare has granted additional reimbursement to Roche’s breast cancer therapy Perjeta (pertuzumab) ...
Posted by Michael Wonder on 20 May 2019
Korean Government to reduce biopharmaceutical approval period to half
20 May 2019 - The Korean government plans to reduce by half the current one and a half years of ...
Posted by Michael Wonder on 07 May 2019
Celgene’s myelodysplastic syndrome treatment gets more insurance benefits
7 May 2019 - The Ministry of Health and Welfare has granted additional reimbursement to Celgene’s multiple myeloma drug, Revlimid (ingredient: ...
Posted by Michael Wonder on 07 May 2019
Roche agreed, MSD and BMS should, too
7 May 2019 - Immunotherapies have become so effective and popular that some cancer patients were cured. However, they are ...
Posted by Michael Wonder on 10 Apr 2019
Biogen’s orphan drug Spinraza to get reimbursement
9 April 2019 - Biogen’s Spinraza (ingredient: nusinersen), a treatment for spinal muscular atrophy (SMA), started to receive insurance benefits as ...
Posted by Michael Wonder on 25 Mar 2019
HIRA puts brakes on Gilead’s AIDS treatment receiving reimbursement
22 March 2019 - The reimbursement plan for Gilead Science Korea’s Biktarvy, an acquired immune deficiency syndrome (AIDS) treatment, has been ...
Posted by Michael Wonder on 18 Mar 2019
Reimbursement for orphan drug Spinraza imminent
18 March 2019 - Biogen’s Spinraza (nusinersen), a treatment for spinal muscular atrophy, is likely to obtain reimbursement as early ...
Posted by Michael Wonder on 27 Feb 2019
Korea’s 30th novel drug K-Cab to get insurance benefit from March
27 February 2019 - Korea’s 30th novel medicine K-Cab Tab. (tegoprazan) will receive insurance coverage, eight months after winning approval, the ...